Human immune organoids to decode B cell response in healthy donors and patients with lymphoma
- Nat Mater. 2025 Feb;24(2):297-311. doi: 10.1038/s41563-024-02037-1.
- 1. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
- 2. George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
- 3. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
- 4. Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
- 5. Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA, USA.
- 6. Emory Vaccine Center, Emory School of Medicine, Emory University, Atlanta, GA, USA.
- 7. School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
- 8. School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.
- 9. School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
- 10. Department of Otolaryngology, Emory School of Medicine, Emory University, Atlanta, GA, USA.
- 11. Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
- 12. Winship Cancer Center, Emory School of Medicine, Emory University, Atlanta, GA, USA.
- 13. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA. [email protected].
- 14. George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. [email protected].
- 15. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. [email protected].
Antibodies are produced when naive B cells differentiate into plasma cells within germinal centres (GCs) of lymphoid tissues. Patients with B cell lymphoma on effective immunotherapies exhibit diminished antibody production, leading to higher Infection rates and reduced vaccine efficacy, even after B cell recovery. Current ex vivo models fail to sustain long-term GC reactions and effectively test B cell responses. Here we developed synthetic hydrogels mimicking the lymphoid tissue microenvironment, enabling human GCs from tonsils and peripheral blood mononuclear cell-derived B cells. Immune organoids derived from peripheral blood mononuclear cells maintain GC B cells and plasma cells longer than tonsil-derived ones and exhibit unique B cell programming, including GC compartments, somatic hypermutation, immunoglobulin class switching and B cell clones. Chemical inhibition of transcriptional and epigenetic processes enhances plasma cell formation. While integrating polarized CXCL12 protein in a lymphoid organ-on-chip modulates GC responses in healthy donor B cells, it fails with B cells derived from patients with lymphoma. Our system allows rapid, controlled modelling of immune responses and B cell disorders.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: OthersResearch Areas: Inflammation/Immunology
-
target: OthersResearch Areas: Inflammation/Immunology